GSTM1 and anemia (phenotype): Studies report that anemia occurs in 40–60% of patients with SAH, with the CONSCIOUS‐1 trial highlighting that a hemoglobin (Hb) level < 10 g/dL was independently associated with poor neurological outcomes and increased mortality [4].